Unknown

Dataset Information

0

Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.


ABSTRACT: Influenza A virus (IAV) is a major cause of respiratory illness. Given the disease severity, associated economic costs, and recent appearance of novel IAV strains, there is a renewed interest in developing novel and efficacious "universal" IAV vaccination strategies. Recent studies have highlighted that immunizations capable of generating local (i.e., nasal mucosa and lung) tissue-resident memory T and B cells in addition to systemic immunity offer the greatest protection against future IAV encounters. Current IAV vaccines are designed to largely stimulate IAV-specific antibodies, but do not generate the lung-resident memory T and B cells induced during IAV infections. Herein, we report on an intranasally administered biocompatible polyanhydride nanoparticle-based IAV vaccine (IAV-nanovax) capable of providing protection against subsequent homologous and heterologous IAV infections in both inbred and outbred populations. Our findings also demonstrate that vaccination with IAV-nanovax promotes the induction of germinal center B cells within the lungs, both systemic and lung local IAV-specific antibodies, and IAV-specific lung-resident memory CD4 and CD8 T cells. Altogether our findings show that an intranasally administered nanovaccine can induce immunity within the lungs, similar to what occurs during IAV infections, and thus could prove useful as a strategy for providing "universal" protection against IAV.

SUBMITTER: Zacharias ZR 

PROVIDER: S-EPMC6127617 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.

Zacharias Zeb R ZR   Ross Kathleen A KA   Hornick Emma E EE   Goodman Jonathan T JT   Narasimhan Balaji B   Waldschmidt Thomas J TJ   Legge Kevin L KL  

Frontiers in immunology 20180828


Influenza A virus (IAV) is a major cause of respiratory illness. Given the disease severity, associated economic costs, and recent appearance of novel IAV strains, there is a renewed interest in developing novel and efficacious "universal" IAV vaccination strategies. Recent studies have highlighted that immunizations capable of generating local (i.e., nasal mucosa and lung) tissue-resident memory T and B cells in addition to systemic immunity offer the greatest protection against future IAV enco  ...[more]

Similar Datasets

| S-EPMC5627305 | biostudies-literature
| S-EPMC7457018 | biostudies-literature
| S-EPMC6754344 | biostudies-literature
| S-EPMC7653089 | biostudies-literature
| S-EPMC8744187 | biostudies-literature
| S-EPMC2346691 | biostudies-literature
| S-EPMC4078824 | biostudies-literature
| S-EPMC7021715 | biostudies-literature
| S-EPMC6584211 | biostudies-literature
| S-EPMC6280892 | biostudies-other